https://www.fresenius.com en-us Thu, 04 Dec 2025 16:00:00 +0100 Thu, 04 Dec 2025 16:00:00 +0100 Thu, 04 Dec 2025 16:00:00 +0100 <![CDATA[Fresenius strengthens biomanufacturing capabilities through AI collaboration]]> Mon, 01 Dec 2025 16:00:00 +0100 <![CDATA[Fresenius Launches Denosumab Biosimilars in EU ]]> Fri, 14 Nov 2025 22:40:00 +0100 <![CDATA[Katrin Kerner and Christian Wagner to lead Group Communications at Fresenius]]> Fri, 14 Nov 2025 19:39:37 +0100 <![CDATA[Fresenius climbs to 2nd place in governance ranking]]> Wed, 05 Nov 2025 13:45:00 +0100 <![CDATA[Fresenius Q3/25: Disciplined execution drives continued strong performance – guidance raised]]> Thu, 25 Sep 2025 23:00:00 +0200 <![CDATA[Fresenius receives Vizient® Awards for Supply and Service Excellence in the U.S.]]> Mon, 15 Sep 2025 20:00:00 +0200 <![CDATA[Key parameter for the 2026 DRG inflator for German hospitals set at 5.17%]]> Tue, 09 Sep 2025 01:30:00 +0200 <![CDATA[Fresenius successfully places bonds with a volume of 1 billion euros]]> Mon, 08 Sep 2025 21:00:00 +0200 <![CDATA[Fresenius receives a €400 million EIB loan to support R&D, innovation and capacity expansion across the EU]]> Mon, 01 Sep 2025 16:00:00 +0200 <![CDATA[Fresenius continues streamlining its operations with the divestment of the Calea homecare business in Canada]]> Tue, 26 Aug 2025 16:14:38 +0200 <![CDATA[Fresenius leads new EASYGEN consortium aimed at decentralizing CAR-T cell therapy and improving hospital workflows]]> here.]]> Wed, 06 Aug 2025 12:45:00 +0200 <![CDATA[Fresenius Q2/25: Guidance raised - Resilient business continues to deliver consistent performance]]> Tue, 05 Aug 2025 15:42:21 +0200 <![CDATA[Fresenius announces licensing agreement with Polpharma Biologics to commercialize a proposed vedolizumab biosimilar candidate]]> Wed, 23 Jul 2025 17:15:00 +0200 <![CDATA[Fresenius Receives European Commission Approval for Denosumab Biosimilars]]> Wed, 16 Jul 2025 21:00:00 +0200 <![CDATA[Fresenius publishes Aide Memoire for the upcoming Q2 2025 reporting]]> website. The results of the second quarter and first half of 2025 of Fresenius SE & Co. KGaA will be published on 6 August 2025. The Quiet Period will start on 24 July 2025. ]]> Thu, 03 Jul 2025 20:55:04 +0200 <![CDATA[Fresenius expands Biopharma Portfolio in the U.S. with Denosumab Biosimilars availability]]> here.]]> Tue, 27 May 2025 17:00:00 +0200 <![CDATA[Anke Schmidt appointed Head of Corporate Communications at Fresenius]]> Tue, 27 May 2025 15:30:00 +0200 <![CDATA[Denosumab CHMP Positive Opinion ]]> Tue, 20 May 2025 21:00:00 +0200 <![CDATA[Fresenius expands its line of Epinephrine injectables in the U.S. ]]> Wed, 07 May 2025 12:45:00 +0200 <![CDATA[Fresenius Q1/25: Strong start to 2025 – #FutureFresenius REJUVENATE phase kicked-off with excellent momentum]]>